Harry Palmin
2022
In 2022, Harry Palmin earned a total compensation of $592.6K as Chief Financial Officer at Opexa Therapeutics, a 6% increase compared to previous year.
Compensation breakdown
| Bonus | $152,960 |
|---|---|
| Option Awards | $47,233 |
| Salary | $392,400 |
| Total | $592,593 |
Palmin received $392.4K in salary, accounting for 66% of the total pay in 2022.
Palmin also received $153K in bonus and $47.2K in option awards.
Rankings
In 2022, Harry Palmin's compensation ranked 3,987th out of 5,505 executives tracked by ExecPay. In other words, Palmin earned more than 27.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,987 out of 5,505 | 28th |
Division Manufacturing | 2,241 out of 2,984 | 25th |
Major group Chemicals And Allied Products | 1,075 out of 1,339 | 20th |
Industry group Drugs | 1,006 out of 1,242 | 19th |
Industry Pharmaceutical Preparations | 730 out of 896 | 19th |
Source: SEC filing on April 14, 2023.
Palmin's colleagues
We found two more compensation records of executives who worked with Harry Palmin at Opexa Therapeutics in 2022.
News
Opexa Therapeutics CEO Chris Schelling's 2022 pay jumps 51% to $834K
April 14, 2023
Opexa Therapeutics Chief Business Officer Jefferson Davis receives $635K in 2021
April 15, 2022
Opexa Therapeutics CEO Chris Schelling's 2020 pay falls 54% to $676K
April 16, 2021
Opexa Therapeutics CEO Chris Schelling's 2019 pay jumps 167% to $1.5M
October 14, 2020
Opexa Therapeutics CEO Chris Schelling's 2018 pay slips 6% to $550K
April 12, 2019